Compare BOOM & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOOM | SABS |
|---|---|---|
| Founded | 1965 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.8M | 187.6M |
| IPO Year | N/A | N/A |
| Metric | BOOM | SABS |
|---|---|---|
| Price | $8.56 | $4.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $8.50 | ★ $9.80 |
| AVG Volume (30 Days) | 159.1K | ★ 370.7K |
| Earning Date | 02-23-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $618,683,000.00 | $114,698.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.46 | $1.00 |
| 52 Week High | $9.92 | $6.60 |
| Indicator | BOOM | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 68.53 | 63.00 |
| Support Level | $8.30 | $3.93 |
| Resistance Level | $9.20 | $4.21 |
| Average True Range (ATR) | 0.37 | 0.28 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 70.76 | 82.17 |
DMC Global Inc operates a diversified family of technical product and process businesses serving the energy, industrial and infrastructure markets. Its business is organized into three segments: Arcadia, DynaEnergetics, and NobelClad. Arcadia Products supplies architectural building products, including exterior and interior framing systems, windows, urtain walls, storefronts etc to the commercial construction market. NobelClad is involved in the production of explosion-welded clad metal plates for use in the construction of corrosion-resistant industrial processing equipment and specialized transition joints. DynaEnergetics driver, designs manufactures and distributes products utilized by the oil and gas industry principally for the perforation of oil and gas wells.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.